Peringatan Keamanan

No toxicological investigation has been completed.

Olmutinib

DB13164

small molecule investigational

Deskripsi

Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals A19196. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

Struktur Molekul 2D

Berat 486.59
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 8-11h [L766].
Volume Distribusi Data not yet available.
Klirens (Clearance) Data not yet available.

Absorpsi

tmax of 3-4h with oral administration L766.

Metabolisme

Data not yet available.

Rute Eliminasi

Data not yet available.

Interaksi Obat

39 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olmutinib.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olmutinib.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Olmutinib.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olmutinib.
Lidocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Quinisocaine.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Olmutinib.
Ambroxol The risk or severity of methemoglobinemia can be increased when Olmutinib is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Olmutinib is combined with Etrasimod.

Target Protein

Epidermal growth factor receptor EGFR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 27912760
    Liao BC, Lin CC, Lee JH, Yang JC: Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016 Dec 3;23(1):86.
  • PMID: 27071706
    Wang S, Cang S, Liu D: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016 Apr 12;9:34. doi: 10.1186/s13045-016-0268-z.
  • PMID: 26898616
    Tan CS, Cho BC, Soo RA: Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8.
  • PMID: 27357069
    Kim ES: Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7. doi: 10.1007/s40265-016-0606-z.
  • PMID: 16226114
    Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T: Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol. 2005 Oct;36(10):1127-34.
  • PMID: 11369216
    Bogdan S, Klambt C: Epidermal growth factor receptor signaling. Curr Biol. 2001 Apr 17;11(8):R292-5.
  • PMID: -
    Kwang O-K, Cha MY, Kim M, Song JY, Lee J-H, Kim YH, Lee Y-M, Suh KH, Son J.: Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor Cancer Res. 2014 October;74(19 Suppl.):Abstract nr LB-100.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul